Kymera Therapeutics, Inc.(KYMR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KYMR Kymera Therapeutics, Inc.

盘后交易 02-25 18:43:41 EST

90.68

-0.33

-0.36%

盘后91.00

+0.32+0.35%

18:09 EST

最高93.64	最低89.06	成交量105.81万
今开91.40	昨收91.01	日振幅5.03%
总市值71.59亿	流通市值49.54亿	总股本7,895万
成交额9,586万	换手率1.94%	流通股本5,463万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KYMR","market":"US","secType":"STK","nameCN":"Kymera Therapeutics, Inc.","latestPrice":90.68,"timestamp":1772053200000,"preClose":91.01,"halted":0,"volume":1058085,"hourTrading":{"tag":"盘后","latestPrice":91,"preClose":90.68,"latestTime":"18:09 EST","volume":16385,"amount":1485806.71035,"timestamp":1772060969633,"change":0.32,"changeRate":0.003529,"amplitude":0.003529},"delay":0,"changeRate":-0.003625975167563985,"floatShares":54626600,"shares":78949000,"eps":-3.597465,"marketStatus":"盘后交易","change":-0.33,"latestTime":"02-25 18:43:41 EST","open":91.4,"high":93.64,"low":89.06,"amount":95856141.90915,"amplitude":0.050324,"askPrice":95,"askSize":1,"bidPrice":91,"bidSize":9,"shortable":3,"etf":0,"ttmEps":-3.597465,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1772067600000},"marketStatusCode":4,"adr":0,"listingDate":1597982400000,"exchange":"NASDAQ","adjPreClose":91.01,"preHourTrading":{"tag":"盘前","latestPrice":91.2,"preClose":91.01,"latestTime":"09:29 EST","volume":8087,"amount":735663.0682,"timestamp":1772029799959,"change":0.19,"changeRate":0.002088,"amplitude":0.02736},"postHourTrading":{"tag":"盘后","latestPrice":91,"preClose":90.68,"latestTime":"18:09 EST","volume":16385,"amount":1485806.71035,"timestamp":1772060969633,"change":0.32,"changeRate":0.003529,"amplitude":0.003529},"volumeRatio":1.41061,"impliedVol":0.7219,"impliedVolPercentile":0.5259},"requestUrl":"/m/hq/s/KYMR/tweets","defaultTab":"tweets","newsList":[{"id":"1143087468","title":"Kymera Therapeutics宣布首例患者完成KT-621给药——首创口服Stat6降解剂进入Breadth二期B阶段哮喘临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1143087468","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143087468?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:01","pubTimestamp":1769688060,"startTime":"0","endTime":"0","summary":"生物技术公司Kymera Therapeutics宣布，其创新药物KT-621已完成针对哮喘患者的首例给药，标志着该口服Stat6降解剂正式进入Breadth二期B阶段临床试验。作为同类首创疗法，KT-621通过靶向降解Stat6蛋白来调节免疫反应，为中重度哮喘患者提供潜在治疗选择。此次临床试验旨在评估KT-621的安全性、耐受性及有效性，预计将纳入多国临床研究中心的重症哮喘患者。该阶段试验数据的收集与分析，将为后续全球临床开发策略提供关键依据。Stat6信号通路在过敏性炎症疾病中扮演核心角色。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"gpt_icon":0},{"id":"1104376733","title":"Kymera Therapeutics Inc. 计划于2026年推进至少一款首创口服免疫学项目的新开发候选药物进入IND阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1104376733","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104376733?lang=zh_cn&edition=full","pubTime":"2026-01-13 20:07","pubTimestamp":1768306058,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics Inc. 近日公布了其研发管线的重要规划，公司计划在2026年前推进至少一款针对首创（First-in-Class）口服免疫学项目的新开发候选药物，旨在向新药临床试验申请（IND）阶段迈进。这一战略部署凸显了公司致力于在免疫治疗领域开拓创新疗法的决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"gpt_icon":0},{"id":"1194110609","title":"Kymera Therapeutics开展的皮炎治疗试验取得了积极进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1194110609","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194110609?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:40","pubTimestamp":1765197643,"startTime":"0","endTime":"0","summary":"实现了深度STAT6降解。","market":"us","thumbnail":"https://static.tigerbbs.com/08ecfd9eac9c3137da2cc8b5e8e15cc0","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/08ecfd9eac9c3137da2cc8b5e8e15cc0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"131f4a8ae97812e1f16587f8e011d27b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Kymera Therapeutics开展的皮炎治疗试验取得了积极进展","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR"],"gpt_icon":0},{"id":"1194478362","title":"盘前｜CFLT、KYMR暴涨，CoreWeave“跳水”，特斯拉跌超1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194478362","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194478362?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:27","pubTimestamp":1765196866,"startTime":"0","endTime":"0","summary":"美股三大指数期货在盘前交易时段小幅上涨。","market":"us","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVNA","CFLT","KYMR"],"gpt_icon":1},{"id":"1153788539","title":"Kymera Therapeutics, Inc. - 在KT-621治疗中观察到所有疾病终点的强健临床活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1153788539","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153788539?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:07","pubTimestamp":1765195631,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. - 在KT-621治疗中观察到所有疾病终点的强健临床活性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"131f4a8ae97812e1f16587f8e011d27b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"gpt_icon":0},{"id":"1118432812","title":"Kymera Therapeutics Inc - KT-621 Broaden2 II期B试验针对严重的阿尔茨海默病仍在进行中，数据预计于2027年中公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1118432812","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118432812?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:04","pubTimestamp":1765195482,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics Inc - KT-621 Broaden2 II期B试验针对严重的阿尔茨海默病仍在进行中，数据预计于2027年中公布","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"1191653930","title":"Kymera Therapeutics公布KT-621的第一阶段B临床试验取得积极结果，该药为首个口服Stat6降解剂，适用于中重度特应性皮炎患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1191653930","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191653930?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:03","pubTimestamp":1765195430,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics公布KT-621的第一阶段B临床试验取得积极结果，该药为首个口服Stat6降解剂，适用于中重度特应性皮炎患者","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"131f4a8ae97812e1f16587f8e011d27b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"1143730690","title":"Kymera Therapeutics将在2025年12月8日公布KT-621扩展1B期特应性皮炎试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1143730690","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143730690?lang=zh_cn&edition=full","pubTime":"2025-12-06 05:02","pubTimestamp":1764968524,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics将在2025年12月8日公布KT-621扩展1B期特应性皮炎试验结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"gpt_icon":0},{"id":"1129014922","title":"Kymera Therapeutics首位患者在Broaden2 II期B临床试验中接受KT-621治疗，这是一种首创的口服Stat6降解剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1129014922","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129014922?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:02","pubTimestamp":1764072160,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics首位患者在Broaden2 II期B特应性皮炎临床试验中接受KT-621治疗，这是一种首创的口服Stat6降解剂","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"1184658612","title":"Kymera Therapeutics宣布将在欧洲皮肤病与性病学会及欧洲呼吸学会大会上发表关于首创口服Stat6降解剂KT-621的最新口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1184658612","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184658612?lang=zh_cn&edition=full","pubTime":"2025-09-17 19:01","pubTimestamp":1758106914,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics宣布将在欧洲皮肤病与性病学会及欧洲呼吸学会大会上发表关于首创口服Stat6降解剂KT-621的最新口头报告","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"gpt_icon":0},{"id":"2517437281","title":"Kymera Therapeutics, Inc.2024财年实现净利润-2.24亿美元，同比减少52.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517437281","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517437281?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363235,"startTime":"0","endTime":"0","summary":"3月8日，Kymera Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-2.24亿美元，同比减少52.38%；其中营业收入为47.07百万美元，同比减少40.11%，每股基本收益为-2.98美元。从资产负债表来看，Kymera Therapeutics, Inc.总负债1.42亿美元，其中短期债务13.11百万美元，资产负债比为6.89，流动比率为0.08。机构评级：截至2025年3月8日，当前有17家机构对Kymera Therapeutics, Inc.目标价做出预测，其中目标均价为58.82美元，其中最低目标价为41.00美元，最高目标价为97.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000043abed65dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000043abed65dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KYMR"],"gpt_icon":0},{"id":"1147904941","title":"异动解读 | Kymera Therapeutics第四季度业绩逊预期 盘中股价大跌7.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=1147904941","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147904941?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:10","pubTimestamp":1740669010,"startTime":"0","endTime":"0","summary":"生物技术公司Kymera Therapeutics今日盘中股价大幅下跌7.27%,引发市场广泛关注。据统计,截至收盘KYMR报33.34美元,成交量3.18万股,振幅4.84%。公司最新公布的2024年第四季度财报显示,KYMR当季每股亏损0.88美元,远高于华尔街分析师预期的0.78美元亏损。与去年同期相比,营收更是大幅下滑84.56%。显而易见,Kymera Therapeutics业绩大幅逊于市场预期,给投资者带来了较大的不确定性和失望。公司财务数据的疲软表现,可能是导致KYMR股价今日大跌的主要诱因之一。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | Kymera Therapeutics第四季度业绩逊预期 盘中股价大跌7.27%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KYMR"],"gpt_icon":0},{"id":"2514385542","title":"Kymera Therapeutics, Inc.盘中异动 早盘大幅跳水5.71%报33.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385542","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514385542?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:40","pubTimestamp":1740667238,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时40分，Kymera Therapeutics, Inc.股票出现异动，股价大幅下跌5.71%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.69%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224039a2567cac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224039a2567cac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KYMR","LENZ","BK4139"],"gpt_icon":0},{"id":"1121089825","title":"Kymera Therapeutics 2024年Q4 GAAP每股收益$(0.88)不及预期$(0.78)，销售额$739万不及预期$1182万","url":"https://stock-news.laohu8.com/highlight/detail?id=1121089825","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121089825?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:07","pubTimestamp":1740658067,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics报告季度每股亏损$，比分析师的共识预期$低12.82%。与去年同期每股亏损$相比，这是252%的下降。以上内容来自Benzinga Earnings专栏，原文如下：Kymera $Therapeutics$  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 12.82 percent. This is a 252 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $7.39 million which missed the analyst consensus estimate of $11.82 million by 37.45 percent.  This is a 84.56 percent decrease over sale","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","LENZ"],"gpt_icon":0},{"id":"2510803663","title":"Kymera Therapeutics, Inc.盘中异动 早盘快速下挫5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510803663","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510803663?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:41","pubTimestamp":1739284909,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时41分，Kymera Therapeutics, Inc.股票出现异动，股价大幅下挫5.13%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.30%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112241499881bf20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112241499881bf20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","KYMR"],"gpt_icon":0},{"id":"2506585786","title":"Kymera Therapeutics, Inc.盘中异动 下午盘股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506585786","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506585786?lang=zh_cn&edition=full","pubTime":"2025-01-28 02:42","pubTimestamp":1738003369,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日02时42分，Kymera Therapeutics, Inc.股票出现异动，股价急速下跌5.03%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.81%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501280242499874d546&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501280242499874d546&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KYMR","BK4139"],"gpt_icon":0},{"id":"2505427022","title":"Kymera Therapeutics, Inc.盘中异动 早盘股价大涨5.59%报42.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505427022","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505427022?lang=zh_cn&edition=full","pubTime":"2025-01-21 23:31","pubTimestamp":1737473477,"startTime":"0","endTime":"0","summary":"北京时间2025年01月21日23时31分，Kymera Therapeutics, Inc.股票出现异动，股价大幅拉升5.59%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.31%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121233117986e3ec5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121233117986e3ec5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","KYMR"],"gpt_icon":0},{"id":"2504946517","title":"Kymera Therapeutics, Inc.盘中异动 急速跳水5.14%报41.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504946517","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504946517?lang=zh_cn&edition=full","pubTime":"2025-01-17 02:19","pubTimestamp":1737051560,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日02时19分，Kymera Therapeutics, Inc.股票出现异动，股价快速下跌5.14%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.36%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117021920abad80f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117021920abad80f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KYMR","LENZ"],"gpt_icon":0},{"id":"2503642508","title":"Kymera Therapeutics, Inc.盘中异动 早盘大幅拉升5.18%报42.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503642508","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503642508?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:32","pubTimestamp":1736951530,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时32分，Kymera Therapeutics, Inc.股票出现异动，股价急速上涨5.18%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.77%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223210ababf25f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223210ababf25f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KYMR","BK4139"],"gpt_icon":0},{"id":"2503572953","title":"Kymera Therapeutics, Inc.盘中异动 早盘股价大涨5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503572953","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503572953?lang=zh_cn&edition=full","pubTime":"2025-01-14 23:06","pubTimestamp":1736867164,"startTime":"0","endTime":"0","summary":"北京时间2025年01月14日23时06分，Kymera Therapeutics, Inc.股票出现异动，股价快速上涨5.15%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114230604986609b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114230604986609b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KYMR","LENZ","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kymeratx.com","stockEarnings":[{"period":"1week","weight":0.0727},{"period":"1month","weight":0.3014},{"period":"3month","weight":0.3411},{"period":"6month","weight":1.1799},{"period":"1year","weight":1.5775},{"period":"ytd","weight":0.1696}],"compareEarnings":[{"period":"1week","weight":0.0066},{"period":"1month","weight":-0.0027},{"period":"3month","weight":0.0113},{"period":"6month","weight":0.0592},{"period":"1year","weight":0.1509},{"period":"ytd","weight":0.008}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kymera Therapeutics, Inc.，一家根据特拉华州法律于2017年5月25日成立的有限责任公司。该公司是一家生物制药公司，致力于发现和开发新颖的小分子疗法，该疗法可通过利用药物选择性地降解致病蛋白。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.060685},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.015472},{"month":3,"riseRate":0.2,"avgChangeRate":-0.073393},{"month":4,"riseRate":0.6,"avgChangeRate":0.013164},{"month":5,"riseRate":0.2,"avgChangeRate":-0.147131},{"month":6,"riseRate":0.6,"avgChangeRate":0.114241},{"month":7,"riseRate":0.8,"avgChangeRate":0.172329},{"month":8,"riseRate":0.6,"avgChangeRate":0.035263},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.031798},{"month":10,"riseRate":0.666667,"avgChangeRate":0.069597},{"month":11,"riseRate":0.666667,"avgChangeRate":0.180891},{"month":12,"riseRate":0.666667,"avgChangeRate":0.094258}],"exchange":"NASDAQ","name":"Kymera Therapeutics, Inc.","nameEN":"Kymera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kymera Therapeutics, Inc.(KYMR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kymera Therapeutics, Inc.(KYMR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kymera Therapeutics, Inc.,KYMR,Kymera Therapeutics, Inc.股票,Kymera Therapeutics, Inc.股票老虎,Kymera Therapeutics, Inc.股票老虎国际,Kymera Therapeutics, Inc.行情,Kymera Therapeutics, Inc.股票行情,Kymera Therapeutics, Inc.股价,Kymera Therapeutics, Inc.股市,Kymera Therapeutics, Inc.股票价格,Kymera Therapeutics, Inc.股票交易,Kymera Therapeutics, Inc.股票购买,Kymera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kymera Therapeutics, Inc.(KYMR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kymera Therapeutics, Inc.(KYMR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}